Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences
MJH Life Sciences

SUBSCRIBE: Print / eNewsletter

ONCOLOGY Table Of Contents

Diagnostic Evaluation of Hepatocellular Carcinoma in a Cirrhotic Liver

June 1, 2000
  • Brian M. Gogel, MD
  • Robert M. Goldstein, MD
  • Joseph A. Kuhn, MD
  • Todd M. Mccarty, MD
  • Amanda Donahoe, MD
  • Karl Glastad, MD

Hepatocellular carcinoma (HCC) is one of the world’s most common cancers. It is closely associated with cirrhosis, especially that due to viral hepatitis. The incidences of viral hepatitis and HCC are rising steadily in the United

  • READ >>
  • Add new comment

AIDS-Related Kaposi’s Sarcoma: Current Treatment Options, Future Trends

June 1, 2000
  • Ronald T. Mitsuyasu, MD

Kaposi’s sarcoma (KS) is the most common malignancy associated with the acquired immunodeficiency syndrome (AIDS). Recent years have witnessed a decline in the overall incidence of AIDS-related KS, as well as a greater

  • READ >>
  • Add new comment

Oral Therapy for Colorectal Cancer: How to Choose

June 1, 2000
  • Henry C. Pitot, MD
  • Richard M. Goldberg, MD

The article by Damjanov and Meropol elegantly outlines the rationale behind the preclinical development of several potential new oral chemotherapy options for patients with advanced colorectal carcinoma and the available data from clinical trials in advanced colorectal cancer that evaluated the activity and safety of these agents. The authors relate the history of fluorinated pyrimidine therapy in colorectal cancer and the pharmacologic challenges to delivering effective oral therapy in a such a way that the chemistry behind the processes becomes readily intelligible. They note that the erratic absorption and blood levels associated with orally administered fluorouracil (5-FU) led to the current approaches to oral therapy.

  • READ >>
  • Add new comment

Magnetic Resonance Imaging of the Abdomen: Applications in the Oncology Patient

June 27, 2000
  • Russell N. Low, MD

Cross-sectional imaging of the abdomen in oncology patients presents unique challenges and opportunities. A close working relationship between the oncologist and radiologist is essential for the exchange of the clinical and

  • READ >>
  • Add new comment

Combination Therapy With Purine Nucleoside Analogs

June 1, 2000
  • Francine M. Foss, MD

Pentostatin (Nipent) has demonstrated significant activity as a single agent in patients with low-grade B- and T-cell lymphomas, but thus far, clinical experience with combinations of pentostatin and other agents is limited. A study

  • READ >>
  • Add new comment

Leuprolide Implant Approved for Once-Yearly Palliative Treatment of Advanced Prostate Cancer

June 1, 2000

The US Food and Drug Administration has
approved ALZA Corporation’s new drug application for a

  • READ >>
  • Add new comment

New Website Addresses Epidermal Growth Factor Receptors in Cancer Therapy

June 1, 2000

AstraZeneca has announced the launch of a new
website that will help keep researchers and physicians up to date on

  • READ >>
  • Add new comment

Common p53 Gene Test Helps Predict Cancer Recurrence in Mastectomy Patients

June 1, 2000

A common blood protein test can predict which breast cancer patients are at risk for recurrence after mastectomy. The test may eventually help direct treatment decisions, speculate researchers from the University of Texas Health Sciences Center at

  • READ >>
  • Add new comment

Infectious Complications of Pentostatin Therapy

June 1, 2000
  • Julie M. Vose, MD
  • Fernando Cabanillas, MD
  • Susan O’Brien, MD
  • Nam Dang, MD, PhD
  • Robert Drapkin, MD
  • Francine M. Foss, MD

Managing the infectious complications associated with pentostatin (Nipent), used alone or in combination with other agents in patients with low-grade lymphomas, poses a significant problem for clinicians. Since there is limited

  • READ >>
  • Add new comment

Promising Results With Targeted Drug Delivery System for Primary Liver Cancer

June 1, 2000

FeRx Incorporated, a privately held development stage drug delivery company, recently reported encouraging data from its phase I/II clinical trial of doxorubicin adsorbed to magnetic targeted carriers (MTC-DOX), for the treatment of patients with

  • READ >>
  • Add new comment

New Treatment Guidelines Available for Colon and Rectal Cancer Patients

June 1, 2000

The American Cancer Society’s translation
of the National Comprehensive Cancer Network (NCCN) guidelines

  • READ >>
  • Add new comment

Eovist Injection and Resovist Injection: Two New Liver-Specific Contrast Agents for MRI

June 1, 2000
  • Jan Mintorovitch, PhD
  • Kohkan Shamsi, MD, PhD

In this short review, we describe two new liver-specific contrast agents for MRI that are in clinical development. The main differences among the liver-specific contrast agents available at present are also discussed briefly.

  • READ >>
  • Add new comment

Commentary (Yang): Surgical Treatment of Metastatic Pulmonary Soft-Tissue Sarcoma

June 1, 2000
  • Stephen C. Yang, MD, FACS

The criteria for successfully resecting pulmonary metastasis have not changed since they were originally described by Ehrenhaft in 1958.[1] They are (1) that the primary tumor site has been removed without evidence of local recurrence, (2) that no extrathoracic organ metastasis exists, and (3) that pulmonary disease has been completely removed without compromising pulmonary function.

  • READ >>
  • Add new comment

Average Charges for Three Types of Hysterectomy Procedures: United States, 1998

June 1, 2000

Each year close to 600,000 women undergo a
hysterectomy in the United States.[1] Although the number of these

  • READ >>
  • Add new comment

Oral Therapy for Colorectal Cancer: How to Choose

June 1, 2000
  • Richard Pazdur, MD

Heidelberger and associates[1] synthesized fluorouracil (5-FU) in 1957 after observing that rat hepatomas utilized radiolabeled uracil more avidly than malignant tissues. For the past 40 years, 5-FU has been extensively investigated in various schedules, in combination with biochemical modulators, and for a variety of malignancies.[2]

  • READ >>
  • Add new comment

Current Status of Voice Restoration Following Total Laryngectomy

June 1, 2000
  • Eric D. Blom, PhD

Total laryngectomy is the surgical procedure traditionally used to treat patients with advanced-stage cancer of the larynx. The impairments resulting from removal of such a small organ are, indeed, profound. They include

  • READ >>
  • Add new comment

Pentostatin and Rituximab in the Treatment of Patients With B-Cell Malignancies

June 1, 2000
  • Robert Drapkin, MD

Both pentostatin (Nipent) and rituximab (Rituxan) have single-agent activity in B-cell malignancies, including indolent and intermediate-grade non-Hodgkin’s lymphoma (NHL). Pentostatin is also active in pretreated patients

  • READ >>
  • Add new comment

Breath Test Identifies Patients Who Should Get Lower Chemotherapy Doses

June 1, 2000

A relatively simple technique, pioneered by a North Carolina physician, can distinguish between patients who can metabolize docetaxel (Taxotere) normally and those who need to receive lower doses for safety, according to a recent study. Researchers

  • READ >>
  • Add new comment

ADA Inhibitors: Recent Developments and Future Directions in Low-Grade Lymphoma

June 1, 2000
  • Julie M. Vose, MD

Pentostatin (Nipent) is a nucleoside analog that inhibits the activity of the enzyme adenosine deaminase. Inhibition of adenosine deaminase blocks the deamination of adenosine to inosine and deoxyadenosine to deoxyinosine in the purine

  • READ >>
  • Add new comment

Encouraging Results Achieved Using Topotecan as Salvage Therapy in Recurrent Ovarian Cancer

June 1, 2000

The results of a new study demonstrate that
one-third of patients with recurrent ovarian cancer who are

  • READ >>
  • Add new comment

Update on Low Malignant Potential Ovarian Tumors

June 1, 2000
  • Andrew W. Menzin, MD

Low malignant potential (LMP) ovarian tumors represent a small subset of epithelial ovarian cancers that were first identified 70 years ago but were recognized in a systematic way only within the last 30 years. These lesions

  • READ >>
  • Add new comment

CD26 in T-Cell Lymphomas: A Potential Clinical Role?

June 1, 2000
  • Srdan Verstovsek, MD, PhD
  • Fernando Cabanillas, MD
  • Nam H. Dang, MD, PhD

T-cell non-Hodgkin’s lymphomas are a heterogeneous group of diseases that differ markedly in terms of their clinical behavior and prognosis. In recently developed classification systems, the sites of initial disease

  • READ >>
  • Add new comment

Purine Nucleoside Analogs in Indolent Non-Hodgkin’s Lymphoma

June 27, 2000
  • Fernando Cabanillas, MD

This article details both the contribution of the purine nucleoside analogs to the current management of relapsed indolent non-Hodgkin’s lymphoma (NHL) and the role of pentostatin (Nipent) in that management. Of the three

  • READ >>
  • Add new comment

3D CRT More Cost-Effective Than Conventional RT for Prostate Cancer

June 1, 2000

Three-dimensional conformal radiation therapy (3D CRT) is more effective yet costs no more than conventional radiation therapy in the long-term treatment of prostate cancer, according to a study conducted at Fox Chase Cancer Center in

  • READ >>
  • Add new comment

Economic Consequences of Cancer Treatment–Related Fatigue

June 1, 2000

Cancer treatment–related fatigue, the most prevalent and debilitating side effect of chemotherapy, has a significant impact on the economic well-being of patients and their caregivers, according to a national survey of more than 300 cancer patients. The

  • READ >>
  • Add new comment

Capecitabine Demonstrates Favorable Response Rates in Advanced Colorectal Cancer Patients

June 1, 2000

Patients with metastatic colorectal cancer may
benefit from therapy with the oral anticancer agent capecitabine

  • READ >>
  • Add new comment

Senate Bill Would Limit Prices Drug Companies Could Charge

June 1, 2000

The perception is that it is normally Democrats
who support price controls; that is why Sen. Slade Gorton (R-WA), who

  • READ >>
  • Add new comment

Commentary (Seidman/Kurman): Update on Low Malignant Potential Ovarian Tumors

June 1, 2000
  • Jeffrey D. Seidman, MD
  • Robert J. Kurman, MD

The borderline category of ovarian tumors is one of the most controversial topics in gynecologic oncology and pathology, and is confusing to both clinicians and patients. Although numerous reviews have appeared in the literature, most of them rehash the prevailing views on borderline tumors without critically evaluating the published data that allegedly validate some rather puzzling and perplexing notions. For example, although these tumors are considered to be a subset of carcinoma, most patients are cured even when they have “metastatic” disease that has been inadequately treated. In addition, reports cite recurrence and death as late as 39 years after the diagnosis of tumors that appear histologically bland and noninvasive.

  • READ >>
  • Add new comment

AIDS-Related Kaposi’s Sarcoma: Current Treatment Options, Future Trends

June 1, 2000
  • Robert Yarchoan, MD

Dr. Mitsuyasu has been doing clinical research in patients with AIDS-related Kaposi’s sarcoma (KS) since the beginning of the AIDS epidemic, and his review reflects this breadth of experience. It provides a well-rounded and up-to-date assessment of the pathophysiology, evaluation, and treatment of AIDS-related KS that should be a useful guide for practicing physicians.

  • READ >>
  • Add new comment

Support for ‘Minority Report’ on Mammography for Women in Their 40s

June 1, 2000

Weighing in unambiguously on the controversy
over the National Institutes of Health (NIH) consensus statement on

  • READ >>
  • Add new comment

Research Challenges Conventional Thinking About Prostate Cancer Treatment

June 1, 2000

Physicians have long known that male hormones fuel prostate cancer growth. That’s why therapies that block the production of androgen—or testosterone—provide some of the most effective therapies for advanced prostate cancer. Certain drugs, for

  • READ >>
  • Add new comment

On Newer Treatments for Lymphoma

June 1, 2000

recent teleconference sponsored by Cancer Care Inc centered on
newer treatments for aggressive lymphomas. Michael Grossbard, MD,

  • READ >>
  • Add new comment

AIDS-Related Kaposi’s Sarcoma: Current Treatment Options, Future Trends

June 1, 2000
  • Bruce J. Dezube, MD

In his excellent review, Dr. Mitsuyasu correctly highlights the three most important ingredients that play a role in the pathogenesis of acquired immunodeficiency syndrome (AIDS)-related Kaposi’s sarcoma (KS)—Kaposi’s sarcoma herpesvirus/human herpesvirus type 8 (KSHV/HHV-8); altered expression and response to cytokines; and stimulation of KS growth by the human immunodeficiency virus (HIV)-1 trans-activating protein, Tat. Recent studies have provided tremendous insight into the process whereby KSHV/HHV-8 creates the inflammatory-angiogenic state that characterizes KS.

  • READ >>
  • Add new comment

Pentostatin Treatment of Cutaneous T-Cell Lymphoma

June 1, 2000
  • Claire Dearden, BSc, MD, FRCP FRCPath
  • Estella Matutes, MD
  • Daniel Catovsky, MD

Mycosis fungoides is an indolent primary cutaneous T-cell lymphoma (CTCL) that usually progresses from localized skin lesions to systemic disease. Sézary syndrome is a distinct variant characterized by generalized

  • READ >>
  • Add new comment

Commentary (Downey/Ginsberg): Surgical Treatment of Metastatic Pulmonary Soft-Tissue Sarcoma

June 1, 2000
  • Robert J. Downey, MD
  • Robert Ginsberg, MD

In their article, Chao and Goldberg provide a concise overview of the literature on pulmonary metastasectomy for sarcoma, including a brief history of the procedure, guidelines for preoperative evaluation, conduct of the operation, and probable outcomes achieved. Several points that they review deserve further discussion.

  • READ >>
  • Add new comment

Study Finds Estrogen May Fuel Lung Cancer Growth

June 1, 2000

Long known to be instrumental in fueling the growth of breast cancer, estrogen may spur the same process in lung cancer, according to the findings of a University of Pittsburgh study presented at the annual meeting of the American Association for

  • READ >>
  • Add new comment

Commentary (Shah): Current Status of Voice Restoration Following Total Laryngectomy

June 1, 2000
  • Jatin P. Shah, MD, FACS

Drs. Mark Singer and Eric Blom revolutionized the process of speech rehabilitation following total laryngectomy with their introduction of the tracheoesophageal puncture and insertion of a duck bill prosthesis.[1-5] The physiologic principles of the procedure are obvious, the surgical technique is simple, and the results in terms of fluent speech production are immediate and quite satisfactory. Dr. Blom is to be complimented for providing in this article, a succinct summary of the “current methods” available for speech rehabilitation for a patient facing total laryngectomy.

  • READ >>
  • Add new comment

Magnetic Resonance Imaging for Intra-abdominal Malignancy

June 1, 2000
  • Todd M. Mccarty, MD

Accurate imaging of the hepatic and extrahepatic abdomen is an important component of the management of many patients with cancer. Historically, clinicians have relied on computed tomography (CT). The use of intravenous (IV) and oral contrast

  • READ >>
  • Add new comment

Breast Cancer

June 1, 2000
  • Daniel F. Roses, MD
  • Lawrence D. Wagman, MD, FACS

This is a comprehensive 701-page volume filled with excellent illustrations, photographs, tables, and schematics. The overall structure of the book takes the reader from molecular oncology issues through pathology, diagnosis, staging, treatment, and a

  • READ >>
  • Add new comment

Comparison Studies of CT and MRI in Patients With Hepatic Metastases

June 1, 2000
  • James P. Earls, MD

The increasing use of systemic and directed liver therapy for patients with hepatic metastases has created a demand for improved accuracy of noninvasive imaging techniques. Computed tomography (CT) and magnetic

  • READ >>
  • Add new comment

AIDS-Related Kaposi’s Sarcoma: Current Treatment Options, Future Trends

June 1, 2000
  • Susan E. Krown, MD

In his article, Dr. Mitsuyasu concisely reviews a large body of data concerning the etiology, pathogenesis, epidemiology, and treatment of Kaposi’s sarcoma (KS) in the setting of the human immunodeficiency virus (HIV) infection. As he correctly points out, effective highly active antiretroviral therapy (HAART), with its consequent improvements in immune function and decrease in production of viral and cytokine cofactors that promote KS growth, has been partly responsible for the decline of KS incidence in areas with ready access to HIV therapy.

  • READ >>
  • Add new comment

Hepatic Imaging With Iron Oxide Magnetic Resonance Imaging

June 1, 2000
  • John F. Schultz, MD
  • Joseph A. Kuhn, MD
  • Todd M. Mccarty, MD

The management of hepatic tumors presents a challenging problem. The natural history of primary and metastatic liver lesions portends a poor prognosis. However, surgical resection and newer ablative techniques have had a

  • READ >>
  • Add new comment

Medicare Makes Some Changes in Outpatient Cancer Clinic Rates

June 1, 2000

Medicare has made some changes in how it will
calculate payments to outpatient cancer clinics when the new

  • READ >>
  • Add new comment

Surgical Treatment of Metastatic Pulmonary Soft-Tissue Sarcoma

June 1, 2000
  • Celia Chao, MD
  • Melvyn Goldberg, MD, FRCS(C), FACS

The lung is the most frequent site of metastasis from soft-tissue sarcomas. Due to the relative resistance of sarcoma to either chemotherapy or radiotherapy, compared to other solid tumors, surgical management of

  • READ >>
  • Add new comment

Oral Therapy for Colorectal Cancer: How to Choose

June 1, 2000
  • Jean L. Grem, MD, FACP

Damjanov and Meropol review the status of several oral fluoropyrimidine drugs that are currently undergoing clinical testing for the treatment of colorectal cancer. Meta-analysis indicates an 8% improvement in the overall response rate and a survival advantage of 0.8 months with infusional vs bolus fluorouracil (5-FU)—arguably small differences. The incidence of grade 3-4 diarrhea, mucositis, and myelosuppression is

  • READ >>
  • Add new comment

Oral Therapy for Colorectal Cancer: How to Choose

June 1, 2000
  • Nevena Damjanov, MD
  • Neal J. Meropol, MD

Either alone or in combination with other antineoplastics, fluorouracil (5-FU) has been the mainstay of treatment of gastrointestinal, breast, and head and neck cancers for the past 40 years. Numerous active 5-FU schedules are in

  • READ >>
  • Add new comment

Commentary (Trimble/Trimble): Update on Low Malignant Potential Ovarian Tumors

June 1, 2000
  • Cornelia Liu Trimble, MD
  • Edward L. Trimble, MD, PhD

Ovarian tumors of low malignant potential (LMP) would benefit from a new name, not to mention a deeper understanding of their biology, effective treatment, and a framework within which they can be studied. Fortunately, for a pathologic entity that is poorly understood and also is unresponsive to current therapy, most LMP ovarian tumors carry a benign prognosis.

  • READ >>
  • Add new comment

Cell Phone Users May Still Be At Risk for Brain Cancer

June 1, 2000

With worldwide use of cellular phones rising exponentially, a team of Swedish medical investigators is raising renewed concerns about the link between brain tumors and cell phones in a new, peer-reviewed article posted on the Medscape

  • READ >>
  • Add new comment

Commentary (Taub): Surgical Treatment of Metastatic Pulmonary Soft-Tissue Sarcoma

June 1, 2000
  • Robert N. Taub, MD, PhD

In their literature survey, Drs. Chao and Goldberg reach the conclusion that surgical metastasectomy is the clear treatment of choice and should be the standard of care for patients with pulmonary recurrences of soft-tissue sarcoma. It is assumed that survival without this operation is negligible, even while there are no survival statistics for sarcoma patients who are eligible for metastasectomy and who choose to forgo this option.

  • READ >>
  • Add new comment

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Breast Cancer
  • Acute Myeloid Leukemia
  • HER2-Positive Breast Cancer
  • Videos Breast Cancer
  • Follicular Lymphoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

ONCOLOGY Vol 33 No 11
Nov 21, 2019 Vol 33 No 11
Subscribe
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".